Promethean1 transparent.png

  • HOME

  • ABOUT US

    • BOARD
    • MANAGEMENT
    • LICENCING
    • GOVERNANCE
    • CEO's LETTER
    • ORIGIN

  • SERVICES

    • SUPPLY CHAIN
    • MANUFACTURING
    • INNOVATION
    • PARTNERSHIPS
    • MEDICAL ADVISORY
    • BRAND STRATEGY

  • PRODUCTS

    • DRIED BUD / FLOWER
    • TINCTURES (EMULSIONS)
    • TOPICALS
    • NOVEL MEDICINES

  • AUSTRALIA

    • PATIENTS

  • NEWS

    • RESOURCES
    • ANNOUNCEMENTS

  • CLINICAL RESOURCES

  • CONTACT

    • INVESTORS

  • More

    Use tab to navigate through the menu items.
    Search
    • Oct 4, 2021

    Therapeutic Goods Administration relaxes the requirements on nicotine as an unregistered medicine

    • Sep 18, 2021

    Novel psychedelic medicines are the next global health revolution

    • Aug 10, 2021

    Sale of TCann to Promethean

    • Jul 5, 2021

    Promethean BioPharma supports the rescheduling of psilocybin and MDMA in Australia

    • Jan 7, 2021

    The Third Promethean Moment

    Announcements

    NAVIGATION

    • HOME
    • ABOUT US
      • BOARD
      • MANAGEMENT
      • LICENCING
      • GOVERNANCE
      • CEO's LETTER
      • ORIGIN
    • SERVICES
      • SUPPLY CHAIN
      • MANUFACTURING
      • INNOVATION
      • PARTNERSHIPS
      • MEDICAL ADVISORY
      • BRAND STRATEGY
    • PRODUCTS
      • DRIED BUD / FLOWER
      • TINCTURES (EMULSIONS)
      • TOPICALS
      • NOVEL MEDICINES
    • AUSTRALIA
      • PATIENTS
    • NEWS
      • RESOURCES
      • ANNOUNCEMENTS
    • CLINICAL RESOURCES
    • CONTACT
      • INVESTORS

    SERVICES WE OFFER

    Supply Chain

    Manufacturing

    Innovation

    Partnerships

    Medical Advisory

    Brand Strategy

    CONTACT US

    contact@prometheanbiopharma.com
    1300 749 330 (Australia)

    • LinkedIn
    Promethean1 transparent.png

    © 2022 Promethean BioPharma Ltd

    All Rights Reserved